For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.09 (7.50%)
Data as of 09/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
09/17/14Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 17, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 – September 30, 2014. ... 
Printer Friendly Version
08/11/14AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan
Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 Congress AV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “Our strategy for building value remains fo... 
Printer Friendly Version
05/31/14AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--May 31, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results wer... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
AACR 2014, Cancer Cachexia Poster #1441, Liu
7th Annual Cachexia Conference, GDF-15 oral presentation
AACR 2013, Cancer Cachexia poster - Abstract 4650, Vigano
AACR 2013, GDF-15 poster - Abstract 3504, Lerner
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.